Page 2453 - Williams Hematology ( PDFDrive )

2424 Index Index 2425

Disseminated intravascular coagulation DNA methyltransferases (DNMTs), 168, 336 for malignant histiocytic diseases, 1110
(DIC), pathogenesis (Cont.): DNA polymerase, 146 for mantle cell lymphoma, 1657t
oxidative stress and vasoactive DNA protein kinase, 1166f, 1167 for μ-heavy-chain disease, 1810
molecules, 2203 DNA repair theory, 130 for mycosis fungoides, 1687
thrombin and platelets, 2200–2201 DNMT3a, 170 for myeloma, 1750, 1752t, 1753t, 1755
pathology, 2199 DNMT3A secondary acute myelogenous leukemia
platelet dysfunction in, 2086 in acute myelogenous leukemia, 226t, and, 183, 1407
during pregnancy, 120–121, 2210–2211 1376, 1377–1378, 1378t thalidomide and, 334
therapy, 2210–2214, 2212f, 2317t, 2318 in clonal myeloid disorders, 1280 DPD (deoxypyridinoline), 1738
underlying diseases, 2207–2210 in myelodysplastic syndromes, 227t, 1346t, DP proteins, 238
aortic aneurysm, 2210 1348, 1349, 1350–1351 DRAP-27. See CD9
brain injury, 2208 in Ph-chromosome negative D region, polymerization defects in, 2158
burns, 2208 myeloproliferative neoplasms, Drepanocytes (sickle cells), 473f, 473t, 474f,
heat stroke, 2209 229t 475
hemangiomas, 2209–2210 DOCK (dedicator of cytokinesis 8) Driver mutations, 1348
hepatic disease, 2193, 2208–2209 deficiency, 1215t, 1221–1222 Drosophila Imd pathway, 303
infectious diseases, 2207 Docosahexaenoic acid, 2079 Drosophila melanogaster, 293
leukemias, 2208 Döhle bodies, 22f, 23 Drugs. See also Antineoplastic drugs/
purpura fulminans, 2207 Dombrock blood group/antigens, 2331t, chemotherapy; specific drugs
snake bites, 2209 2337, 2345–2346t aplastic anemia induced by, 515–516, 517t
solid tumors, 803–804, 2207–2208 Dominance, 147, 148 erythema multiforme induced by, 2106,
transfusion reaction, 2210 Donath-Landsteiner antibody, 824, 829, 835 2106f
trauma, 2208 Donath-Landsteiner autoantibody, 823 hemolysis induced by, 553, 706–707
Disulfide bonds, of heavy and light chains, Donath-Landsteiner hemolytic anemia, 824, hemolytic anemia induced by, 708, 708t,
1159 824t 710, 810t
Divalent metal transporter (DMT)-1, 619, Donor cells, recurrent leukemia in, 1401 lymphocytopenia induced by, 1205–1206,
623, 623f Donor lymphocyte infusions (DLI), 359, 373, 1205t
Divalent metal transporter (DMT)-1 1400–1401, 1462 lymphocytosis induced by, 1203–1204
mutations, 642 Doripenem, 384, 387t marrow suppression induced by, 553
DIVA regimen, 1408 Dosage compensation, 150 maternal, effects on fetus and newborn,
DKC1, 530–531 DOT1, 169 112, 112t
DKK1 (Dickkopf-1), 1713, 1737, 1738, 1739f DOT1L, 225 megaloblastic anemia caused by, 596t, 605,
DLBCL. See Diffuse large B-cell lymphoma DOT1L inhibitors, 170, 337, 1403 606t
(DLBCL) Double-helix model, 145, 146f methemoglobinemia induced by, 789, 790t,
DLI (donor lymphocyte infusions), 359, 373, Double-hit lymphoma, 1502, 1596, 1633, 792, 793
1400–1401, 1462 1674 neutropenia induced by, 985, 992, 996–
DNA Double-stranded RNA (dsRNA), 295, 298, 997, 998t
antisense, 153 301 neutrophilia induced by, 1001
cloning, 152 Downeast anemia, 704 neutrophil motility impairment and, 1026
complementary. See Complementary DNA Down syndrome. See Trisomy 21 platelet disorders induced by, 2073–2079,
(cDNA) Doxorubicin, 327–328. See also ABVD 2074t
functions, 145–146 regimen; BEACOPP regimen; purpuras induced by, 2107
hydroxymethylation, 162 CHOP regimen; CODOX-M/ red cell aplasia induced by, 543
methylation, 162 IVAC regimen; EPOCH regimen; sulfhemoglobinemia induced by, 793
replication, megaloblastic anemia and, 593 HyperCVAD regimen; Stanford V thrombocytopenia induced by, 2015–2018,
sequencing, 152, 155. See also Next- regimen 2016t, 2017t
generation sequencing for acute lymphoblastic leukemia, 1515, thrombotic microangiopathy induced by,
structure, 145, 146f 1516 428, 431, 2262–2263
synthesis, 587f for acute myelogenous leukemia vasculitis induced by, 2106, 2106f
DNA damage checkpoint, 213 in children, 1409 Drug use/abuse, history of, 6
DNA-dependent activator of IRFs (DAI), in pregnant patients, 1409 Drüsenfieber, 1261
302f, 303 adverse effects, 328, 1519t dRVVT (dilute Russell viper venom time),
DNA ligase IV, 1167 for α-heavy-chain disease, 1808 2241, 2243
DNA ligase IV deficiency, 530t for Burkitt lymphoma, 1676 Dryness of the mouth, history of, 5
DNA methylation/demethylation, 168–170, for diffuse large B-cell lymphoma, 1629t dsRNA (double-stranded RNA), 295, 298,
1349 for Hodgkin lymphoma, 1616 301

Kaushansky_index_p2393-2506.indd 2424 9/21/15 3:21 PM